While many see Elias Zerhouni's attempt to make his support for new investigators permanent NIH policy a good thing, DrugMonkey doesn't think the issue of who-gets-what is so clear-cut. He says it's the inherent bias in peer review that needs to be changed, and that Band-Aid solutions like the so-called affirmative action favoring young or first-time grant applicants are masking the real problem. "How so?